Skip to main content
Search

Biologics as a treatment strategy in food allergy

Published on May 30, 2024   32 min

Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms

Please wait while the transcript is being prepared...
0:00
Hello. My name is Sayantani Sindher. I'm a Clinical Associate Professor at Stanford University and I am the Director of the Clinical Translational Research Unit at the Sean N. Parker Center for Allergy and Asthma Research. Today, I will be discussing biologics as a treatment strategy for food allergy.
0:20
I have to disclose some grant support I have received from the NIH, Regeneron, DBV technologies, Aimmune, Novartis, CoFR, and FARE for the conduct of food allergy-related clinical trials. I have also served as an advisory committee member for Genentech and DBV technologies.
0:43
Food allergy is when your immune system mounts an inappropriate response to food antigens. This process is initiated when allergenic proteins are presented by antigen-presenting cells to naïve T cells which induce a Th2 response to the allergens leading to the production of allergen-specific immunoglobulin E or IgE which becomes displayed on the surface of mast cells and basophils. In subsequent exposures, the allergen interacts with the IgE on the surface of mast cells and basophils which causes degranulation and initiates the allergic symptoms that we are familiar with.
1:28
The most severe and concerning consequence of these reactions is the potential for anaphylaxis which can lead to life-threatening if not rapidly treated with epinephrine followed by the examination by a medical professional. Anaphylaxis includes the involvement of one's CNS system, cutaneous system, cardiovascular, respiratory as well as gastrointestinal systems among others.
Show
Hide

Biologics as a treatment strategy in food allergy

Embed in course/own notes